WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year
MWN-AI** Summary
WuXi Biologics (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has been recognized as a constituent of the FTSE4Good Index Series for the fifth consecutive year, highlighting its ongoing commitment to sustainability. Established by FTSE Russell in 2001, the FTSE4Good Index Series evaluates companies based on their Environmental, Social, and Governance (ESG) practices across 23 developed and 20 emerging countries.
WuXi Biologics has consistently demonstrated strong performance in various ESG criteria, particularly excelling in corporate governance, labor standards, and anti-corruption measures. Dr. Chris Chen, CEO and Chairman of the company's ESG Committee, expressed pride in the recognition, emphasizing its dedication to driving sustainability in the CRDMO sector. The company aligns its practices with the United Nations Sustainable Development Goals and has actively engaged with initiatives such as the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative.
Recently, WuXi Biologics established near-term and net-zero greenhouse gas emissions reduction targets that have been approved by the Science Based Targets initiative (SBTi). The company has garnered various accolades for its sustainability endeavors, including the EcoVadis Platinum Medal, recognition in the Dow Jones Sustainability Indices, and inclusion in the CDP Water Security "A List."
With a workforce of over 12,000 across multiple countries, WuXi Biologics is dedicated to providing efficient and cost-effective biologics solutions. The company's mission revolves around sustainability as a cornerstone for long-term growth, driving green technology innovations, and fostering positive social and environmental impacts in collaboration with all stakeholders. This latest recognition from FTSE Russell underscores WuXi Biologics' status as a leader in sustainable practices within the industry.
MWN-AI** Analysis
WuXi Biologics’ inclusion in the FTSE4Good Index Series for the fifth consecutive year underscores its significant commitment to sustainability and governance practices—factors increasingly valued by investors. This recognition not only reinforces WuXi’s position as a leader in the Contract Research, Development, and Manufacturing Organization (CRDMO) sector but also highlights the growing importance of Environmental, Social, and Governance (ESG) criteria in investment decisions.
For investors, the FTSE4Good certification provides a robust signal regarding a company's dedication to sustainable practices. As more institutional investors incorporate ESG criteria into their portfolio strategies, WuXi Biologics stands to benefit from increased demand for its stock. Given the rising backlash against companies that fail to meet sustainability standards, WuXi’s strong ESG performance positions it favorably in a market that is shifting towards responsible investment.
Sustainability initiatives, especially those aligned with the United Nations Sustainable Development Goals, not only support the company’s ethical obligations but can enhance operational efficiencies and reduce costs over time. WuXi’s recent achievements in environmental metrics, such as its near-term and net-zero greenhouse gas emissions targets approved by the Science Based Targets initiative, further bolster its market appeal.
As a financial analyst, I advise investors to consider incorporating WuXi Biologics into their portfolios, given its solid ESG credentials and the trend towards sustainable investing. The company's robust performance in these areas may lead to long-term financial stability and growth. With the pharmaceutical industry’s ongoing evolution and the increasing focus on biopharmaceutical advancements, WuXi Biologics is well-positioned to leverage emerging opportunities while reinforcing its commitment to sustainability.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
SHANGHAI , Sept. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been selected as a constituent company of the FTSE4Good Index Series, marking the fifth consecutive year the company has been recognized by FTSE Russell for outstanding sustainability performance.
The FTSE4Good Index Series, launched in 2001 by FTSE Russell (now part of the London Stock Exchange Group), is a family of equity indices designed to measure the performance of companies demonstrating strong Environmental, Social, and Governance (ESG) practices. The Series serves as a benchmark for investors seeking to align their portfolios with sustainability goals.
Inclusion in the FTSE4Good Index Series is based on independent analysis of data from over 23 developed countries and 20 emerging countries. WuXi Biologics has consistently demonstrated exceptional performance in its FTSE Russell ESG ratings over the past five years, most specifically in the areas of corporate governance, anti-corruption, labor standards, and water security.
Dr. Chris Chen , CEO of WuXi Biologics and Chairman of its ESG Committee , commented, "We are very pleased to be selected again as a constituent of FTSE4Good Index Series, an acknowledgement that further inspires our steadfast dedication to driving sustainability. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions, and work together with all stakeholders to promote sustainable practices."
In line with United Nations Sustainable Development Goals, WuXi Biologics has been actively engaged with United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI) to deliver positive impacts. Recently, the company's new near-term and net-zero greenhouse gas emissions reduction target matrix has been approved by Science Based Targets initiative (SBTi).
Over the past few years, WuXi Biologics has earned widespread recognition for its dedicated efforts in sustainability. The company was awarded EcoVadis Platinum Medal; listed in Dow Jones Sustainability Indices; named to CDP Water Security "A List" and Supplier Engagement Assessment "A List", and awarded a CDP Climate Change leadership-level "A-" score; given the highest negligible-risk rating by Sustainalytics, and recognized as Sustainalytics industry and regional ESG top-rated company; listed in Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.
About FTSE4Good Index Series
Created by the global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE4Good indexes are used by a wide variety of market participants to create and assess responsible investment funds and other products.
FTSE Russell evaluations are based on performance in areas such as Corporate Governance, Health & Safety, Anti-Corruption and Climate Change.? Businesses included in the FTSE4Good Index Series meet a variety of environmental, social and governance criteria.
For more information, please visit: https://www.lseg.com/en/ftse-russell/indices/ftse4good .
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China , the United States , Ireland , Germany and Singapore , WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024 , WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com .
Contacts
Media
PR@wuxibiologics.com
SOURCE WuXi Biologics
FAQ**
How does WuXi Biologics Cayman Inc ADR WXXWY plan to maintain its strong ESG performance to ensure consecutive years of inclusion in the FTSE4Good Index Series beyond 2025?
In what specific areas has WuXi Biologics Cayman Inc ADR WXXWY improved its sustainability practices to achieve its fifth consecutive inclusion in the FTSE4Good Index Series?
What initiatives does WuXi Biologics Cayman Inc ADR WXXWY have in place to further align with the United Nations Sustainable Development Goals while supporting global partners?
How does the recognition of WuXi Biologics Cayman Inc ADR WXXWY in the FTSE4Good Index Series impact its investor relations and long-term business growth strategies?
**MWN-AI FAQ is based on asking OpenAI questions about Wuxi Biologics Cayman Inc ADR (OTC: WXXWY).
NASDAQ: WXXWY
WXXWY Trading
0.66% G/L:
$9.16 Last:
3,992 Volume:
$8.96 Open:
